Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
VVOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.98 - $7.95
Previous CloseN/A
Volume144.69K
Average Volume (3M)1.40M
Market Cap
$27.27M
Enterprise Value$20.52M
Total Cash (Recent Filing)$2.34M
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 13, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding5,889,520
10 Day Avg. Volume208,924
30 Day Avg. Volume1,401,313
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue1.40
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$2.25Price Target Upside-48.86% Downside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Cost ControlOperating expenses in Q4 FY24 were down 21% yoy to $4.9 million, reflecting the company’s ongoing focus on cost control.
Regulatory ApprovalsFDA approves use of Vivos CARE appliances to treat moderate to severe OSA in children, a first in the industry.
Revenue GrowthVivos's new selling model can result in 4-6 times as much revenue per case while accessing many more patients with healthy margins.
Bears Say
Financing ConcernsThe need for additional financing presents the likelihood of further dilutive financing in the next few quarters.
Operational StrategyThe company is transitioning its go-to-market strategy to direct alliances with sleep medicine specialists, aiming to expand its sleep testing partnership nationally.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $1.98 and its highest was $7.95 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $27.27M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Aug 13, 2025 which is in 4 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on May 15, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.45.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Overvalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 5,889,520 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$0.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.993%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
Vivos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.25 (-48.86% Downside)
$2.25 (-48.86% Downside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.48%
12-Months-Change
Fundamentals
Return on Equity
-450.47%
Trailing 12-Months
Asset Growth
-4.42%
Trailing 12-Months
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
VVOS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call outlined significant strategic shifts and growth potential through the SCN acquisition and pediatric product line, but financial challenges remain with declining service revenue, increased losses, and reduced cash reserves. The Rebis alliance's underperformance also highlights potential integration risks.View all VVOS earnings summariesVVOS Stock 12 Month Forecast
Average Price Target
$2.25
▼(-48.86% Downside)
Technical Analysis
Accelerate Diagnostics
―
Co-Diagnostics
―
PAVmed
―
BioSig Technologies
―
Adagio Medical Holdings
―
Ownership Overview
1.24%
Insiders
1.19% Mutual Funds
<0.01% Other Institutional Investors
96.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---